Aurinia Pharmaceuticals Inc.
AUPH
$7.77
-$0.15-1.89%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 24.18% | 32.76% | 24.32% | 37.83% | 46.19% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 24.18% | 32.76% | 24.32% | 37.83% | 46.19% |
| Cost of Revenue | 7.62% | -12.57% | -55.42% | -8.61% | -2.03% |
| Gross Profit | 30.13% | 56.79% | 71.90% | 62.03% | 77.63% |
| SG&A Expenses | -57.36% | -26.04% | -11.29% | -4.56% | -4.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 207.37% | -56.08% | 72.93% | 92.01% | -1,522.41% |
| Total Operating Expenses | -31.28% | -24.37% | -20.85% | -0.05% | -11.13% |
| Operating Income | 455.86% | 132.73% | 172.24% | 97.27% | 77.79% |
| Income Before Tax | 343.25% | 104.44% | 212.61% | 112.18% | 61.16% |
| Income Tax Expenses | 35.99% | -155.77% | 53.36% | 217.76% | 69.50% |
| Earnings from Continuing Operations | 317.17% | 105.32% | 206.72% | 106.28% | 58.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 317.17% | 105.32% | 206.72% | 106.28% | 58.98% |
| EBIT | 455.86% | 132.73% | 172.24% | 97.27% | 77.79% |
| EBITDA | 1,738.77% | 167.17% | 251.27% | 128.49% | 94.03% |
| EPS Basic | 325.20% | 105.37% | 206.59% | 106.21% | 59.39% |
| Normalized Basic EPS | 908.33% | 162.86% | 212.52% | 120.90% | 87.25% |
| EPS Diluted | 314.48% | 105.37% | 206.27% | 106.21% | 59.39% |
| Normalized Diluted EPS | 884.72% | 160.52% | 210.43% | 120.90% | 87.25% |
| Average Basic Shares Outstanding | -3.54% | -0.52% | 0.14% | 0.39% | 0.96% |
| Average Diluted Shares Outstanding | -0.57% | 3.32% | 1.96% | 0.93% | 0.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |